Effect of Orexin System on Nicotine Addiction and Its Neural Mechanism

NCT ID: NCT05947162

Last Updated: 2023-10-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-01

Study Completion Date

2027-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to reveal the role and mechanism of orexin in nicotine addicts, compared to healthy control. The main questions it aims to answer are:

* Whether nicotine addiction-related behaviors, including nicotine withdrawal symptoms, cue-induced increased psychological craving, and relapse behavior are related to plasma orexin levels ?
* What is the neural mechanism of the orexin system in the fMRI brain network?

Participants will be asked to do as followed:

1. Day 1: Fill in the scale, test the concentration of exhaled CO, collect 5ml of blood from the vein, and take about 60 minutes.
2. Day 1-3: Test and record the amount of smoking for 3 days, about 5 minutes.
3. Day 4-5: Collect fMRI data, for about 60 minutes, perform extinction training, for about 30 minutes
4. Day 6: Fill in the scale, test the concentration of CO in exhaled breath, collect 5ml of venous blood, test after subsidence and ignition test, and collect fMRI data, for about 60 minutes.
5. Follow-up (2 weeks/4 weeks): Complete the follow-up on smoking craving and relapse by phone within 2 weeks, about 5 minutes, and complete the scale and collect fMRI data in the 4th week, about 60 minutes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Smoking has always been a serious public health problem in my country. Nicotine is the main addictive ingredient in tobacco, the mechanism of nicotine addiction is not yet clear, and there is a lack of effective means to intervene in nicotine addiction. In recent years, the role of the orexin system in nicotine addiction has attracted great attention. Multiple preclinical studies have consistently found that orexin receptor antagonists have a significant intervention effect on nicotine addiction. Objective: This study focuses on the role and mechanism of orexin in nicotine addiction, and will reveal the neurobiological basis of orexin in nicotine addicts after withdrawal, and its potential as a biomarker for predicting and preventing relapse possible. Methods: This study will combine neuropsychology, neuroimaging, and detection of plasma orexin expression levels to explore whether nicotine addiction-related behaviors, including nicotine withdrawal symptoms, cue-induced increased psychological craving, and relapse behavior are related to plasma orexin Levels are associated, and further explore the neural mechanism of its brain network. Based on the detection of plasma orexin, it is of great theoretical and clinical significance to verify whether it is used as a peripheral blood biomarker of nicotine addiction and to establish an objective evaluation index of nicotine addiction. More specifically, participants need to finish following aims:

1. Scale evaluation: Minnesota Tobacco Withdrawal Symptom Scale, Smoking Craving Scale, Short Smoking Craving Questionnaire, Nicotine Dependence Level Test to evaluate nicotine dependence and Smoking Intensity Index Scale, and record the subjects' smoking index (smoking Years × number of cigarettes smoked per day/20), and the smoking craving visual analog scale was used to indicate the degree of smoking craving. In addition, the Montreal Cognitive Scale, Barratt Impulsivity Scale, Self-Rating Anxiety Scale, Self-Rating Depression Scale, Hamilton Anxiety and Depression Scale and Pittsburgh Sleep Scale were collected for about 60 minutes.
2. Behavioral extinction training: On the 4th and 5th days, combined with cue exposure therapy, nicotine addicts were repeatedly presented with nicotine cue/neutral cue picture stimulation for extinction training, which lasted for 25 minutes.
3. Collect fMRI data: including resting state fMRI and task state fMRI on the 4th and 6th day, about 60 minutes.
4. Detection of blood orexin level: 5ml of venous blood was collected on the 1st, 4th, and 6th day, and the plasma orexin-A level was measured by enzyme-linked immunosorbent assay.
5. Time and method of follow-up: Follow up the subjects through outpatient clinics, telephone, WeChat, etc., record the relapse situation within 2 weeks after the intervention, record the number of cigarettes smoked every day, and return after 1 month for nicotine withdrawal Symptoms and smoking cravings were assessed, and DTI, resting state fMRI and task state fMRI data were collected for about 60 minutes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tobacco Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

smoking cessation combining with nicotine cue extinction training

Participants should stop smoking after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.

Group Type EXPERIMENTAL

extinction training (nicotine cues)

Intervention Type BEHAVIORAL

extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.

Time-restricted smoking cessation

Intervention Type BEHAVIORAL

Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.

smoking cessation combining with neutral cue extinction training

Participants should stop smoking after 18:00 the night before the test, they are combined with cue exposure therapy, by repeatedly presenting neutral cue picture stimuli to nicotine addicts, and performing extinction training for 25 minutes.

Group Type PLACEBO_COMPARATOR

extinction training (neutral cues)

Intervention Type BEHAVIORAL

extinction training: were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.

Time-restricted smoking cessation

Intervention Type BEHAVIORAL

Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.

smoking cessation combining with fasting and nicotine cue extinction training

Participants should stop smoking and eating food after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts are repeatedly presented with nicotine cue picture stimuli for extinction training, which lasts for 25 minutes.

Group Type EXPERIMENTAL

extinction training (nicotine cues)

Intervention Type BEHAVIORAL

extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.

Time-restricted smoking cessation

Intervention Type BEHAVIORAL

Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.

Time-restricted fasting

Intervention Type BEHAVIORAL

Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 10:00 am.

smoking cessation combining with fasting and neutral cue extinction training

Participants should stop smoking and eating food after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.

Group Type PLACEBO_COMPARATOR

extinction training (neutral cues)

Intervention Type BEHAVIORAL

extinction training: were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.

Time-restricted smoking cessation

Intervention Type BEHAVIORAL

Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.

Time-restricted fasting

Intervention Type BEHAVIORAL

Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 10:00 am.

smoking cessation combining with early lifting of fast and nicotine cue extinction training

Participants should stop smoking and eating food after 18:00 the night before the test. After breakfast at 8:00 in the morning, they are combined with cue exposure therapy, by repeatedly presenting neutral cue picture stimuli to nicotine addicts, and performing extinction training for 25 minutes.

Group Type SHAM_COMPARATOR

extinction training (nicotine cues)

Intervention Type BEHAVIORAL

extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.

Time-restricted smoking cessation

Intervention Type BEHAVIORAL

Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.

Time-restricted fasting with food supplemnet

Intervention Type BEHAVIORAL

Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 8:00 am, then supplied with breakfast.

healthy control

Non-smoker healthy subjects matched with the smoking group in terms of age, gender, education level, etc. were used as the control group. Those healthy participants will finish fMRI scanning task.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

extinction training (nicotine cues)

extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.

Intervention Type BEHAVIORAL

extinction training (neutral cues)

extinction training: were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.

Intervention Type BEHAVIORAL

Time-restricted smoking cessation

Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.

Intervention Type BEHAVIORAL

Time-restricted fasting

Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 10:00 am.

Intervention Type BEHAVIORAL

Time-restricted fasting with food supplemnet

Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 8:00 am, then supplied with breakfast.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dietary intervention Dietary intervention

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Nicotine addicts who meet the DSM-V diagnostic criteria for substance dependence, that is, smoking ≥ 10 cigarettes per day and smoking age ≥ 2 years;
2. Communicate normally with the researcher and cooperate with the researchers;

Exclusion Criteria

1. Psychotic symptoms or a family history of mental disorders;
2. A history of dependence or behavior (gambling, online games) addiction other than alcohol, drugs, etc.;
3. Use benzodiazepines or received antipsychotic drugs within 2 weeks;
4. Epilepsy, craniocerebral injury history, coma history, brain organic or serious physical disease;
5. Body mass index (BMI) \> 30 ;
6. Can not tolerate magnetic resonance examinations.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shenzhen Kangning Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Huang Gengdi

Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gengdi Huang, PhD

Role: PRINCIPAL_INVESTIGATOR

Shenzhen Kangning Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shenzhen Kangning Hospital

Shenzhen, Guangdong, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gengdi Huang, PhD

Role: CONTACT

+86 18600251858

Qi Wang, PhD

Role: CONTACT

+86 13688819667

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Qi Wang, Phd

Role: primary

+86 13688819667

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-K002-01-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of Smoking Abstinence
NCT01035632 COMPLETED
Non-Nicotine Agents for Smoking Cessation
NCT00108537 COMPLETED PHASE3